TMCnet News
ABL Nominated for Two Vaccine Industry Excellence Awards: Best CMO & Best CROABL, Inc. (ABL) announced today that they have been nominated for two Vaccine Industry Excellence awards, known as ViE awards. The goal of the ViE awards is to recognize industry leaders with the greatest achievements in the past 12 months within 10 categories. ABL is being considered for both the Best Contract Manufacturing Organization (CMO) and as Best Contract Research Organization (CRO). Some recent accomplishments that qualify ABL for Best CMO include:
Highlights for Best CRO include:
Winners will be announced at the World Vaccine Congress ViE Awards Dinner on April 10th. Winners are decided partially on industry voting and by the ViE awards Scientific Advisory Board. You can follow the link if you would like to review other award categories and vote. Initial voting ends February 24th. About ABL, Inc. ABL, Inc. is a global biomedical contract research and manufacturing organization dedicated to advancing vaccines, therapeutics, and other biologic products. ABL has extensive experience working with diverse organizations. With GMP facilities meeting U.S. and European regulatory standards, ABL's manufacturing services include process and assay development, GMP biologics manufacturing of bulk drug substance, GMP aseptic fill and finish of drug product, and QC analytics. ABL also maintains U.S. and European immunological and molecular laboratories to support preclinical and GCLP clinical sample processing and testing. ABL is a part of the Institut Mérieux, a group of companies dedicated to developing translational science for better patient care globally. For more information on ABL and our services, please visit our website at www.ablinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170222006246/en/ |